My guest this week is Dr. Matt Redinbo from the University of North Carolina at Chapel Hill. Matt has had a remarkable career in both academia and industry. He discusses the challenges of translating basic research and the importance of doing the killer experiment as soon as possible. We talk about his evolution from focusing solely on human enzymes for drug metabolism to studying microbes, and the vast potential for the microbiome as a novel drug target.